IBI 323
Alternative Names: Anti-LAG-3/PD-L1; Anti-LAG-3/PD-L1 bispecific antibody; IBI-323Latest Information Update: 28 Jul 2024
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Recurrent) in China (IV, Infusion)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Recurrent, Second-line therapy or greater) in China (IV, Infusion)
- 14 Apr 2023 Phase-II clinical trials in Solid tumours (IV), prior to April 2023 (Innovent Biologics pipeline, April 2023)